Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial

BACKGROUND: The Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR) showed that patients with coronavirus disease 2019 (COVID-19) pneumonia and increased levels of interleukin (IL)-6 might benefit from blockade of the IL-6 pathway. However, the benefit from this intervention might not be u...

Descripción completa

Detalles Bibliográficos
Autores principales: Trigo-Rodríguez, Marta, Cárcel, Sheila, Navas, Ana, Espíndola-Gómez, Reinaldo, Garrido-Gracia, José Carlos, Esteban Moreno, María Ángeles, León-López, Rafael, Pérez-Crespo, Pedro María Martínez, Alonso, Eduardo Aguilar, Vinuesa, David, Romero-Palacios, Alberto, Pérez-Camacho, Inés, Gutiérrez-Gutiérrez, Belén, Martínez-Marcos, Francisco Javier, Fernández-Roldán, Concepción, León, Eva, Caño, Alexandra Aceituno, Corzo-Delgado, Juan E, Perez-Nadales, Elena, Riazzo, Cristina, de la Fuente, Carmen, Jurado, Aurora, Torre-Cisneros, Julián, Merchante, Nicolás
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077828/
https://www.ncbi.nlm.nih.gov/pubmed/37035487
http://dx.doi.org/10.1093/ofid/ofad133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077828/
https://www.ncbi.nlm.nih.gov/pubmed/37035487
http://dx.doi.org/10.1093/ofid/ofad133

Ejemplares similares